Clinical Trials, Industry, Research and Development, Vaccines
June 16, 2021
Via: Pharma TimesThe study, co-authored by Seqirus, was conducted as part of a Phase III clinical trial of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. The co-administration sub-study enrolled a total of 431 volunteers, all of whom had received a flu vaccine […]
Cell and Gene Therapy, Industry
June 15, 2021
Via: Pharma TimesThe Phase III STAR study enrolled 169 adult males with a genetically confirmed diagnosis of choroideremia. It evaluated the safety and efficacy of a single subretinal injection of the investigational gene therapy. The primary endpoint was the proportion of patients […]
June 14, 2021
Via: Genetic Engineering and Biotechnology NewsThe good news about vaccines and variants continues to roll in. Last week, a study reported that Johnson & Johnson’s COVID-19 vaccine protected against all of the SARS-CoV-2 variants of concern. Now, Pfizer’s COVID-19 vaccine has been shown to protect […]
June 14, 2021
Via: PharmaphorumThe problems at the plant run by contract manufacturer Emergent BioSolutions first emerged a few weeks ago, after an FDA inspection uncovered a string of violations including that the building was “not maintained in a clean and sanitary condition.” While […]
June 11, 2021
Via: Medical NewsThe National Comprehensive Cancer Network (NCCN) today announced the publication of new guidance on COVID-19 vaccines for people with cancer, intended to clear up confusion for patients and caregivers. The new four-page patient guide is based on the latest expert […]
June 11, 2021
Via: PharmaphorumThat will hold back the biotech’s Covaxin shot by several months, and the delay put pressure on Ocugen’s share price, which fell more than 25% after the announcement. The Philadelphia-based company said it had taken the decision to go down […]
June 10, 2021
Via: PharmaphorumThe scientists examined real-world public health data from all individuals in Scotland who received either the AZ or Pfizer/BioNTech vaccines up until 14 April and found a possible association between the AZ shot and an autoimmune disorder called idiopathic thrombocytopenic […]
Mergers and Acquisitions, News
June 9, 2021
Via: PMLiVEThe treatment, being developed by Merck in collaboration with Ridgeback Biotherapeutics, is currently being evaluated in a phase 3 clinical trial. The trial, know as the MOVe-OUT study, is evaluating molnupiravir in the treatment of non-hospitalised patients with laboratory-confirmed COVID-19 […]
Cell and Gene Therapy, Industry
June 9, 2021
Via: Biopharma DiveBeigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several […]
Manufacturing, Research and Development
June 8, 2021
Via: FiercePharmaAfter investigating America’s supply chains, including those for drugs and pharmaceutical ingredients, the Biden administration has revelations to share—and it’s proposing a sweeping strategy to boost domestic drug production. Under the plan, the White House is establishing a public-private partnership […]
June 8, 2021
Via: EPM MagazineCyGenica raised the money in a seed fund investment round led by global venture capital investor SOSV. CyGenica will use the funding to accelerate the validation of its technology which is designed to enable safe, targeted and affordable intercellular drug […]
Cell and Gene Therapy, Industry
June 7, 2021
Via: Biopharma DiveThe approvals of Roche’s Luxturna (2017) for inherited retinal disease and Novartis’ Zolgensma (2019) for spinal muscular atrophy are indicative of a resurgence in the gene therapy field after a decline due to the death of a patient in 1999. […]
Copyright © 2021. All rights reserved
